Tenax Therapeutics continues advancing oral levosimendan as a treatment for pulmonary hypertension linked to heart failure with preserved ejection fraction (PH-HFpEF), completing enrollment in the LEVEL Phase 3 trial and expecting topline data in August 2026. The company maintains a robust liquidity position with $118 million cash and no debt as of mid-2026, though it acknowledges substantial future capital needs beyond current cash to complete trials, file regulatory applications, and commercialize potential approvals. Tenax’s business model remains typical of clinical-stage biotechs—no product revenue yet, heavy reliance on equity financing and licensing agreements, and exposure to regulatory risk. Its proprietary oral formulation offers differentiation in a congested heart failure indication, but milestone payment obligations and ongoing net losses underscore operational challenges ahead.